Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/26/2022 | $7.00 | Buy | Aegis Capital |
BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biopharmaceutical company, is pleased to announce today a change of its corporate name to Scinai Immunotherapeutics Ltd. ("Scinai"). In the past two years, the Company has substantially revamped its senior management team and pharmaceuticals development programs and recently announced its expansion into the CDMO business under the banner Scinai Bioservices. The new corporate name, which was approved by the Israeli authorities on August 31, is the Company's latest step to better reflect its fresh start and new direction. Scinai and its new symbol, "SCNI", will debut on Nasdaq tomorrow.
BiondVax Pharmaceuticals (NASDAQ:BVXV) reported quarterly losses of $(0.00) per share. This is a 99.85 percent increase over losses of $(2.00) per share from the same period last year.
SC 13G - Scinai Immunotherapeutics Ltd. (0001611747) (Subject)
SC 13G/A - Scinai Immunotherapeutics Ltd. (0001611747) (Subject)
SC 13G/A - Scinai Immunotherapeutics Ltd. (0001611747) (Subject)
3/A - BiondVax Pharmaceuticals Ltd. (0001611747) (Issuer)
3/A - BiondVax Pharmaceuticals Ltd. (0001611747) (Issuer)
3/A - BiondVax Pharmaceuticals Ltd. (0001611747) (Issuer)
EFFECT - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)
F-3 - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)
6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)
Aegis Capital initiated coverage of BiondVax Pharmaceuticals with a rating of Buy and set a new price target of $7.00
JERUSALEM, Sept. 06, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biopharmaceutical company, is pleased to announce today a change of its corporate name to Scinai Immunotherapeutics Ltd. ("Scinai"). In the past two years, the Company has substantially revamped its senior management team and pharmaceuticals development programs and recently announced its expansion into the CDMO business under the banner Scinai Bioservices. The new corporate name, which was approved by the Israeli authorities on August 31, is the Company's latest step to better reflect its fresh start and new direction. Scinai and its new symbol, "SCNI", will debut on Nasdaq tomorro
JERUSALEM, Aug. 11, 2023 (GLOBE NEWSWIRE) -- via IBN - BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced the publication today of its financial results for the second quarter ended June 30, 2023, and provided a business update. Second Quarter 2023 Financial Summary R&D expenses for the three months ended June 30, 2023, amounted to $1.45 million compared with $1.97 million for the three months ended June 30, 2022.Marketing, general and administrative expenses for the three months ended June 30, 2
JERUSALEM, Aug. 01, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced that Nasdaq reviewed BiondVax's multi-faceted plan to regain compliance with Nasdaq's Listing Rule 5550(b) and provided it an extension until October 30, 2023, to demonstrate compliance. As previously disclosed, BiondVax received a deficiency letter dated May 1, 2023, from Nasdaq notifying the Company that it is not in compliance with the minimum stockholders' equity requirement for con
JERUSALEM, Jan. 28, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today announced its third quarter financial results for the quarter ended September 30, 2020. Third Quarter 2020 Financial Summary Results are in New Israel Shekels (NIS) and convenience translation to $US is provided using the exchange rate of 3.441 (NIS/$US) as at September 30, 2020. Total operating income for the third quarter was NIS 55.6 million (approximately $16.1 million) compared with a total operating loss of NI
JERUSALEM, Jan. 21, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on development and manufacturing of products for the prevention and treatment of infectious diseases, today announced the appointment of Amir Reichman as its new CEO. Mr. Reichman and Ron Babecoff, BiondVax's founder and current CEO, will share duties during a transition period while Mr. Reichman completes his work obligations at GlaxoSmithKline (GSK), a global pharmaceutical company. Effective March 2, 2021, Mr. Reichman will assume the CEO position full time and Mr. Babecoff will continue as Senior Advisor to the Company. Continue Reading BiondVa